These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Concentration/response relations for the multiple antiarrhythmic actions of sotalol. Woosley RL; Barbey JT; Wang T; Funck-Brentano C Am J Cardiol; 1990 Jan; 65(2):22A-27A; discussion 35A-36A. PubMed ID: 2294688 [TBL] [Abstract][Full Text] [Related]
25. Sotalol: a new agent for the treatment of ventricular arrhythmias. Samoil D; Grubb BP; Temesy-Armos PN Am J Med Sci; 1994 Jan; 307(1):49-53. PubMed ID: 8291508 [TBL] [Abstract][Full Text] [Related]
26. Sotalol: a new beta-adrenergic blocker for ventricular arrhythmias. Cavusoglu E; Frishman WH Prog Cardiovasc Dis; 1995; 37(6):423-40. PubMed ID: 7777671 [TBL] [Abstract][Full Text] [Related]
27. Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent. Singh BN Am J Cardiol; 1996 Aug; 78(4A):41-53. PubMed ID: 8780328 [TBL] [Abstract][Full Text] [Related]
28. The side effect profile of class III antiarrhythmic drugs: focus on d,l-sotalol. MacNeil DJ Am J Cardiol; 1997 Oct; 80(8A):90G-98G. PubMed ID: 9354416 [TBL] [Abstract][Full Text] [Related]
29. Emerging class III antiarrhythmic agents: mechanism of action and proarrhythmic potential. Nair LA; Grant AO Cardiovasc Drugs Ther; 1997 Apr; 11(2):149-67. PubMed ID: 9140692 [TBL] [Abstract][Full Text] [Related]
30. Monotherapy versus combination therapy with class III antiarrhythmic agents to attenuate transmural dispersion of repolarization: a potential risk factor for torsade de pointes. Shah SA; Kluger J; White CM Pharmacotherapy; 2007 Sep; 27(9):1297-305. PubMed ID: 17723083 [TBL] [Abstract][Full Text] [Related]
31. Sotalol: from "just another beta blocker" to "the prototype of class III antidysrhythmic compound". Claudel JP; Touboul P Pacing Clin Electrophysiol; 1995 Mar; 18(3 Pt 1):451-67. PubMed ID: 7770366 [TBL] [Abstract][Full Text] [Related]
32. Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation. Eckardt L; Breithardt G; Haverkamp W J Pharmacol Exp Ther; 2002 Jan; 300(1):64-71. PubMed ID: 11752098 [TBL] [Abstract][Full Text] [Related]
33. Sotalol: Current Status and Expanding Indications. Singh BN J Cardiovasc Pharmacol Ther; 1999 Jan; 4(1):49-65. PubMed ID: 10684524 [TBL] [Abstract][Full Text] [Related]
34. Antiarrhythmic drugs and torsade de pointes. Lazzara R Eur Heart J; 1993 Nov; 14 Suppl H():88-92. PubMed ID: 8293758 [TBL] [Abstract][Full Text] [Related]
35. Efficacy and proarrhythmia of oral sotalol in pediatric patients. Pfammatter JP; Paul T; Lehmann C; Kallfelz HC J Am Coll Cardiol; 1995 Oct; 26(4):1002-7. PubMed ID: 7560592 [TBL] [Abstract][Full Text] [Related]
36. Usefulness of sotalol for life-threatening ventricular arrhythmias. Roden DM Am J Cardiol; 1993 Aug; 72(4):51A-55A. PubMed ID: 8346727 [TBL] [Abstract][Full Text] [Related]
37. Pharmacologic and pharmacokinetic profile of class III antiarrhythmic drugs. Kowey PR; Marinchak RA; Rials SJ; Bharucha D Am J Cardiol; 1997 Oct; 80(8A):16G-23G. PubMed ID: 9354408 [TBL] [Abstract][Full Text] [Related]
39. Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome. Milberg P; Tegelkamp R; Osada N; Schimpf R; Wolpert C; Breithardt G; Borggrefe M; Eckardt L J Cardiovasc Electrophysiol; 2007 Jun; 18(6):658-64. PubMed ID: 17521304 [TBL] [Abstract][Full Text] [Related]
40. Efficacy and adverse effects of sotalol in adults with congenital heart disease. Moore BM; Cordina RL; McGuire MA; Celermajer DS Int J Cardiol; 2019 Jan; 274():74-79. PubMed ID: 29954667 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]